CDK4 and breast carcinoma: Since then, the FDA approved two additional CDK4/6 inhibitors and the combination of CDK4/6 inhibitors and endocrine therapy in the first- or second-line setting is now considered the standard of care for advanced ER+ breast carcinoma [6]; however, the development of resistance to CDK4/6 inhibitors is inevitable in patients undergoing this treatment.